Table 4.
Prevalence of HPV-DNA detection in semen of seronegative vaccine-sensitive patients (Seronegative VSP), seroconverted vaccine-sensitive patients (Seroconverted VSP) and patients of the vaccine arm.
| Seronegative VSP (N = 30) |
Seroconverted VSP (N = 19) |
Patients of the vaccine arm (N = 42) |
|
|---|---|---|---|
| Time-point | Prevalence of HPV-DNA detection in semen (%) | Prevalence of HPV-DNA detection in semen (%) | Prevalence of HPV-DNA detection in semen (%) |
| t0 | 30 (100%) | 19 (100%) | 42 (100%) |
| t3 | N.P. | N.P. | 31 (74%) |
| t6 | 26 (87%) | 16 (84%) | 17 (40%)a,c |
| t9 | N.P. | N.P. | 3 (7%) |
| t12 | 22 (73%) | 8 (42%)a | 0b,d |
| t18 | 10 (33%) | 1 (5%)a | 0 |
| t24 | 7 (23%) | 0 (0%)a | 0 |
Abbreviations: t0: recruitment; t3, t6, t9, t12, t18, t24: 3, 6, 9, 12, 18 and 24 months from recruitment respectively; N.P.: not performed.
Significance: a = P < 0.05 vs seronegative VSP; b = P < 0.001 vs seronegative VSP; c = P < 0.05 vs seroconverted VSP; d = P < 0.001 vs seroconverted VSP.